Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies. It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and compositions useful in such methods. The chelated radionuclides may be a DOTAM-lead (Pb) chelate.

Abstract: The disclosed technologies address various technical and user experience problems by augmenting the functionality provided by virtual on-screen trackpads without requiring users to switch between modes. In this way, users can access extended functionality without interfering with expected traditional trackpad functionality (e.g. moving a cursor, clicking, and scrolling). In particular, technologies are disclosed for modeless digital pen input to a virtual trackpad, modeless gestures for summoning user interfaces, modeless gestures utilizing position relative to adjacent user interfaces, and modeless cursor control and interaction with virtual touch targets.

Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: A computing device detects a press of a global shortcut key simultaneously with a first press and release of a modifier key. In response thereto, an operation is initiated in a non-default display region. The operation might be displaying a user interface element in the non-default display region. The computing device can also detect a second press and release of the modifier key simultaneously with the press of the global shortcut key. In response thereto, the operation can be initiated in a second display region, such as a default display region. The second press and release of the modifier key can be detected within a predetermined period of time following the detection of the first press and release of the modifier key. The operation might be simultaneously initiated in multiple display regions, such as sharing a region that encompasses the non-default display region and one or more other display regions.

Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Abstract: Techniques for providing adaptive assistive technology for assisting users with visual impairment can be used on a computing device. These techniques include displaying content to a user, capturing a series of images or video of the user using a camera, analyzing the series of images or video to determine whether the user is exhibiting behavior or characteristics indicative of visual impairment, and rendering a magnification user interface on the display configured to magnify at least a portion of the content of the display based on a determination that the user is exhibiting behavior or characteristics indicative of visual impairment. The magnification user interface may be controlled based on head and/or eye movements of the user of the computing device.

Abstract: The disclosed technologies address various technical problems, including improving human-computer interaction, by augmenting the functionality provided by user input devices using a digital glove. For example, a digital glove can be utilized to provide pressure sensitivity for non-pressure sensitive touchscreen devices, attribute input made with a digital pen to a user wearing the digital glove, augment the functionality provided by mice and other types of handheld user input devices, augment the functionality provided gaze tracking systems, improve camera-based motion tracking systems, and to augment the functionality provided by speech recognition systems.

Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Abstract: The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Abstract: Implementations described herein provide a component system that reconfigures interchangeable computing device components based on a current state of the computing device. The current state of the computing device is determined based on a hardware configuration of the device, a shell configuration describing software and firmware of the device, and/or context information describing a relationship between the device and its surrounding environment. Based on the current state of the computing device, an output is determined that specifies interchangeable components are to be activated and deactivated. The output is useable to reconfigure individual computing device functionalities, control a manner in which applications execute on the computing device, and adapt the computing device to its current state.

Abstract: A computing device detects a press of a global shortcut key simultaneously with a first press and release of a modifier key. In response thereto, an operation is initiated in a non-default display region. The operation might be displaying a user interface element in the non-default display region. The computing device can also detect a second press and release of the modifier key simultaneously with the press of the global shortcut key. In response thereto, the operation can be initiated in a second display region, such as a default display region. The second press and release of the modifier key can be detected within a predetermined period of time following the detection of the first press and release of the modifier key. The operation might be simultaneously initiated in multiple display regions, such as sharing a region that encompasses the non-default display region and one or more other display regions.

Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.